Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab
Authors
Keywords
-
Journal
Journal of Ovarian Research
Volume 5, Issue 1, Pages 23
Publisher
Springer Nature
Online
2012-09-19
DOI
10.1186/1757-2215-5-23
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy
- (2011) Sang Joon Shin et al. INVESTIGATIONAL NEW DRUGS
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
- (2010) Amir Abdollahi et al. DRUG RESISTANCE UPDATES
- Hallmarks of cancer: Interactions with the tumor stroma
- (2010) Kristian Pietras et al. EXPERIMENTAL CELL RESEARCH
- The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab
- (2010) M.P. Smerdel et al. GYNECOLOGIC ONCOLOGY
- Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
- (2010) Ernest S. Han et al. GYNECOLOGIC ONCOLOGY
- Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab
- (2009) A. Calleri et al. CLINICAL CANCER RESEARCH
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Clinical biomarkers of angiogenesis inhibition
- (2008) Aaron P. Brown et al. CANCER AND METASTASIS REVIEWS
- Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
- (2008) Russell J. Schilder et al. JOURNAL OF CLINICAL ONCOLOGY
- Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients
- (2007) David Loven et al. ACTA ONCOLOGICA
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now